Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1

Evidence suggests that nevirapine, a non-nucleoside reversetranscriptase inhibitor, might be very effective in the prevention of HIV-1 integration and the reduction of risk of HIV-1 acquisition after exposure. We used a triple combination regimen, including nevirapine, for prophylaxis after occupati...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2001-03, Vol.357 (9257), p.687-688
Main Authors: Benn, Paul D, Mercey, Danielle E, Brink, Nicola, Scott, Geoffrey, Williams, Ian G
Format: Article
Language:English
Subjects:
Anti-HIV Agents - adverse effects
Anti-HIV Agents - therapeutic use
Antiretroviral agents
Biological and medical sciences
Drug therapy
Drug Therapy, Combination
Exposure
Female
HIV
HIV Infections - prevention & control
HIV-1
Human immunodeficiency virus
Human viral diseases
Humans
Infectious diseases
Male
Medical research
Medical sciences
Nevirapine - adverse effects
Nevirapine - therapeutic use
Occupational Exposure
Prophylaxis
Reverse Transcriptase Inhibitors - adverse effects
Reverse Transcriptase Inhibitors - therapeutic use
Sexual Behavior
Sexually transmitted diseases
Side effects
STD
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Evidence suggests that nevirapine, a non-nucleoside reversetranscriptase inhibitor, might be very effective in the prevention of HIV-1 integration and the reduction of risk of HIV-1 acquisition after exposure. We used a triple combination regimen, including nevirapine, for prophylaxis after occupational or sexual exposure to HIV-1 infection. Of 57 individuals who started therapy, only 41 returned for follow-up. Five had a grade three or four drug-induced hepatitis, two of whom also had a rash. This high rate of major adverse events raises concerns over the safety of such a regimen for its use in this population.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(00)04139-8